Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Skeletal dysplasia with wormian bone-multiple fractures-dentinogenesis imperfecta is a skeletal disorder, reported in three patients to date, characterized clinically by multiple fractures, wormian bones of the skull, dentinogenesis imperfecta and facial dysmorphism (hypertelorism, periorbital fullness). Although the signs are very similar to osteogenesis imperfecta, characteristic cortical defects in the absence of osteopenia and collagen abnormalities are considered to be distinctive. There have been no further descriptions in the literature since 1999.
Features include very common findings: Dentinogenesis imperfecta and Concave nasal ridge; and common findings: Dolichocephaly, Hypertelorism, Periorbital fullness, and Wormian bones and others. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 4 | Limitation of joint mobility, Wormian bones, Pathologic fracture |
Biomarker and diagnostic research for wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia has been reported in the published literature.
Phenotype severity distribution: 2 very common features, 8 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia.
114 publications have been identified in PubMed for wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia. Research spans Review / Meta-Analysis (69%), Basic Science / Preclinical (11%), and Epidemiology / Natural History (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 79 | 69% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Arms and legs |
3 |
Short foot, Toe clinodactyly, Upper limb undergrowth |
Muscles | 1 | Limitation of joint mobility |
Growth and development | 1 | Short stature |
Laboratory research |
12 |
11% |
Disease patterns and progression | 8 | 7% |
Patient case studies | 4 | 4% |
New treatment approaches | 4 | 4% |
Testing and diagnosis research | 3 | 3% |
Other research | 2 | 2% |
Clinical study results | 2 | 2% |
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Gene Therapy / Novel Therapeutics]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Mak CCY (2025). [PMID: 40280028](https://pubmed.ncbi.nlm.nih.gov/40280028/). *EBioMedicine*. [Diagnostic / Biomarker]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Dev Med Child Neurol*. [Review / Meta-Analysis]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Kaul A (2025). [PMID: 40915300](https://pubmed.ncbi.nlm.nih.gov/40915300/). *Lancet Rheumatol*. [Review / Meta-Analysis]
Zoref-Lorenz A (2025). [PMID: 39656557](https://pubmed.ncbi.nlm.nih.gov/39656557/). *Leuk Lymphoma*. [Review / Meta-Analysis]
Li C (2025). [PMID: 40736845](https://pubmed.ncbi.nlm.nih.gov/40736845/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Sullivan MM (2025). [PMID: 40153327](https://pubmed.ncbi.nlm.nih.gov/40153327/). *Clin Exp Rheumatol*. [Review / Meta-Analysis]